David Berry joined Flagship in 2005 where he focuses on innovating, entrepreneuring, and investing in new ventures in life sciences and sustainability. He is a founder of Flagship portfolio companies Joule Unlimited, Eleven Biotherapeutics (NASDAQ: EBIO), Seres Health, Pronutria, LS9 (acquired by Renewable Energy Group) and Symbiota. David has served as founding CEO of Joule, Pronutria and Seres. He currently serves on the boards of Eleven, Seres, Pronutria and Avedro. He was previously a board member of CGI Pharmaceuticals (acquired by Gilead), Joule and Symbiota.
Prior to Flagship, David received an M.D. from Harvard Medical School and a Ph.D., from the MIT Biological Engineering Division, working in the laboratories of Professors Ram Sasisekharan and Bob Langer, completing the dual degree in just over five years.